The Technical Analyst
AIM ImmunoTech Inc [AIM]
Exchange: AMEX Sector: Healthcare Industry: Biotechnology
AIM ImmunoTech Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-8.38% $0.400
America/New_York / 10 mai 2024 @ 15:59
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 20.36 mill |
| EPS: | -0.600 |
| P/E: | -0.670 |
| Earnings Date: | May 16, 2024 |
| SharesOutstanding: | 50.89 mill |
| Avg Daily Volume: | 0.223 mill |
| RATING 2024-05-10 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.670 | sector: PE -4.07 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.670 | industry: PE -5.55 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.283 (-170.78%) $-0.683 |
| Date: 2024-05-12 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.345 - 0.455 ( +/- 13.75%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-05-06 | Equels Thomas K | Buy | 61 729 | Common Stock |
| 2024-05-06 | Rodino Peter W Iii | Buy | 30 865 | Common Stock |
| 2023-11-30 | Rodino Peter W Iii | Buy | 100 000 | Options |
| 2023-11-30 | Equels Thomas K | Buy | 300 000 | Options |
| 2024-03-21 | Bryan Nancy | Buy | 38 462 | Common Stock |
| INSIDER POWER |
|---|
| 90.41 |
| Last 98 transactions |
| Buy: 4 074 490 | Sell: 118 208 |
Forecast:
16:00 - $0.400
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.400
Forecast 2: 16:00 - $0.400
Forecast 3: 16:00 - $0.400
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.400 (-8.38% ) |
| Volume | 0.0891 mill |
| Avg. Vol. | 0.223 mill |
| % of Avg. Vol | 39.88 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For AIM
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
AIM
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat genital warts, a sexually transmitted disease. It has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
Last 10 Buy Signals
Latest Press Releases
2024-05-09 08:50:00 - Press Release
Aim Immunotech To Discuss First Quarter 2024 Financial Results On May 16, 2024, And Host Conference Call And Webcast
Ocala, fla., may 09, 2024 (globe newswire) -- aim immunotech inc. (nyse american: aim) (“aim” or the “company”) announced today that management will host a conference call and webcast to discuss the company's q1 2024 operational and financial results on thursday, may 16, 2024, at 8:30 am et.
2024-05-06 08:30:00 - Press Release
Aim Immunotech Completes Cgmp Manufacturing Of Clinical Vials Of Ampligen®
Ocala, fla., may 06, 2024 (globe newswire) -- aim immunotech inc. (nyse american: aim) (“aim” or the “company”) today announced the successfully completion of cgmp manufacturing of 9,042 clinical vials of ampligen ® (rintatolimod), aim's dsrna product candidate being developed for globally important cancers, viral diseases and disorders of the immune system.
2024-04-29 08:55:00 - Press Release
Aim Immunotech Announces First Dose Level Is Generally Well-tolerated In Phase 1b/2 Study Of Ampligen And Imfinzi As A Combination Therapy For Late-stage Pancreatic Cancer
Ocala, fla., april 29, 2024 (globe newswire) -- aim immunotech inc. (nyse american: aim) (“aim” or the “company”) today announced that it has taken an essential step forward in testing the combination of aim's ampligen® (rintatolimod) and astrazeneca's anti-pd-l1 immune checkpoint inhibitor imfinzi® (durvalumab) in the treatment of late-stage pancreatic cancer (the “duripanc” study).
2024-04-25 08:45:00 - Press Release
Aim Immunotech Announces Release Of The Next Ceo Corner Segment
Ocala, fla., april 25, 2024 (globe newswire) -- aim immunotech inc. (nyse american: aim) (“aim” or the “company”), today announced the next ceo corner segment has been published on the company's website. for the ceo corner segment, thomas equels, chief executive officer of aim immunotech, gave an overview of metastatic pancreatic cancer and the ongoing phase 1b/2 clinical trial combining aim's ampligen® (rintatolimod) with astrazeneca's anti-pd-l1 immune checkpoint inhibitor imfinzi® (durvalumab) for the treatment of late-stage pancreatic cancer (the “duripanc study”).
2024-04-18 08:45:00 - Press Release
Aim Immunotech Announces Release Of The Next Ceo Corner Segment
Ocala, fla., april 18, 2024 (globe newswire) -- aim immunotech inc. (nyse american: aim) (“aim” or the “company”), today announced the next ceo corner segment has been published on the company's website. for the ceo corner segment, thomas equels, chief executive officer of aim immunotech, gave an overview of locally advanced pancreatic adenocarcinoma and the unmet need.
Latest News
2024-05-09 08:50:00 - GlobeNewsWire
AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast
OCALA, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call and webcast to discuss the Company's Q1 2024 operational and financial results on Thursday, May 16, 2024, at 8:30 AM ET.
2024-04-02 11:32:08 - Seeking Alpha
AIM ImmunoTech Inc. (AIM) Q4 2023 Earnings Call Transcript
AIM ImmunoTech Inc. (NYSE:AIM ) Q4 2023 Earnings Conference Call April 2, 2024 8:30 AM ET Company Participants Thomas Equels - Chief Executive Officer Dr. Christopher McAleer - Scientific Officer Conference Call Participants James Molloy - Alliance Global Partners Ed Woo - Ascendiant Capital Markets Operator Hello. And welcome to the AIM ImmunoTech Fiscal Year 2023 Update Conference Call and Webcast.
2024-03-28 08:05:00 - GlobeNewsWire
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
OCALA, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K.
2024-03-26 09:05:00 - GlobeNewsWire
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast
OCALA, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call and webcast to discuss the Company's Q4/FY2023 operational and financial results on Tuesday, April 2, 2024, at 8:30 AM ET.
2023-11-14 14:20:02 - Seeking Alpha
Aimia, Inc. (AIMFF) Q3 2023 Earnings Call Transcript
Aimia, Inc. (OTCPK:AIMFF) Q3 2023 Earnings Conference Call November 14, 2023 8:30 AM ET Company Participants Albert Matousek - IR Phil Mittleman - CEO Michael Lehmann - President Steve Leonard - CFO Conference Call Participants Brian Morrison - TD Bank Group Operator Good morning, ladies and gentlemen, and welcome to the Aimia, Inc Third Quarter 2023 Results Conference Call. [Operator Instructions].
2023-11-09 08:05:00 - GlobeNewsWire
AIM ImmunoTech to Discuss Third Quarter 2023 Financial Results on November 15, 2023 and Host Conference Call and Webcast
OCALA, Fla., Nov. 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that management will host a conference call and webcast to discuss the Company's Q3 2023 operational and financial results on Wednesday, November 15, 2023 at 8:30 AM ET.
2023-09-22 09:05:00 - GlobeNewsWire
AIM ImmunoTech Selected to Present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
OCALA, Fla., Sept. 22, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced Chris McAleer, Ph.D., Scientific Officer of AIM will present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care being held at the Roswell Park Comprehensive Cancer Center in Buffalo, N.Y., September 20-22, 2023. In addition to the presentation, the Company is proud to announce its sponsorship of the event.
2023-09-05 09:05:00 - GlobeNewsWire
AIM ImmunoTech to Present at the H.C. Wainwright 25th Annual Global Investment Conference
OCALA, Fla., Sept. 05, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K. Equels, Chief Executive Officer of AIM, will present at the H.C. Wainwright 25 th Annual Global Investment Conference being held September 11-13, 2023 in New York, NY and virtually.
2023-08-09 09:05:00 - GlobeNewsWire
AIM ImmunoTech to Discuss Second Quarter 2023 Financial Results on August 15, 2023, and Host Conference Call and Webcast
OCALA, Fla., Aug. 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call and webcast to discuss the Company's Q2 2023 operational and financial results on Tuesday, August 15, 2023 at 8:30 AM ET.
2023-06-14 08:45:00 - GlobeNewsWire
AIM ImmunoTech to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
OCALA, Fla., June 14, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced that Thomas K Equels, M.S.